Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome

Author:

Jeon Jouhyun1ORCID,Olkhov-Mitsel Ekaterina2,Xie Honglei1,Yao Cindy Q1,Zhao Fang2,Jahangiri Sahar3,Cuizon Carmelle2,Scarcello Seville3,Jeyapala Renu2,Watson John D1,Fraser Michael1,Ray Jessica3,Commisso Kristina3,Loblaw Andrew3,Fleshner Neil E4,Bristow Robert G456,Downes Michelle1,Vesprini Danny3,Liu Stanley35ORCID,Bapat Bharati27,Boutros Paul C158910

Affiliation:

1. Ontario Institute for Cancer Research, Toronto, ON, Canada

2. Lunenfeld-Tannenbaum Research Institute, Sinai Health System, Toronto, ON, Canada

3. Sunnybrook Research Institute and Department of Radiation Oncology, Sunnybrook-Odette Cancer Centre, Toronto, ON, Canada

4. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

5. Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada

6. Manchester Cancer Research Centre, University of Manchester, Manchester, UK

7. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

8. Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada

9. Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA

10. Department of Urology, University of California, Los Angeles, Los Angeles, CA

Abstract

Abstract Background The development of noninvasive tests for the early detection of aggressive prostate tumors is a major unmet clinical need. miRNAs are promising noninvasive biomarkers: they play essential roles in tumorigenesis, are stable under diverse analytical conditions, and can be detected in body fluids. Methods We measured the longitudinal stability of 673 miRNAs by collecting serial urine samples from 10 patients with localized prostate cancer. We then measured temporally stable miRNAs in an independent training cohort (n = 99) and created a biomarker predictive of Gleason grade using machine-learning techniques. Finally, we validated this biomarker in an independent validation cohort (n = 40). Results We found that each individual has a specific urine miRNA fingerprint. These fingerprints are temporally stable and associated with specific biological functions. We identified seven miRNAs that were stable over time within individual patients and integrated them with machine-learning techniques to create a novel biomarker for prostate cancer that overcomes interindividual variability. Our urine biomarker robustly identified high-risk patients and achieved similar accuracy as tissue-based prognostic markers (area under the receiver operating characteristic = 0.72, 95% confidence interval = 0.69 to 0.76 in the training cohort, and area under the receiver operating characteristic curve = 0.74, 95% confidence interval = 0.55 to 0.92 in the validation cohort). Conclusions These data highlight the importance of quantifying intra- and intertumoral heterogeneity in biomarker development. This noninvasive biomarker may usefully supplement invasive or expensive radiologic- and tissue-based assays.

Funder

Ontario Institute for Cancer Research

Terry Fox Research Institute New Investigator Award

Canadian Institutes of Health Research New Investigator Award

Movember Foundation

Ontario Ministry of Research and Innovation Early Researcher Award

Canadian Cancer Society, Relay for Life

National Institutes of Health, National Cancer Institute

National Cancer Institute Early Detection Research Network

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3